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The p53 tumor suppressor protein has the ability to transactivate its target genes 
whose gene products are involved in carrying out cell cycle arrest, apoptosis, DNA 
repair, and senescence. Here, I report that two genes may be p53 regulated. Utilizing a 
microarray method to search for novel p53 target genes, I was able to identify a possible 
transcriptional target of p53 being solute carrier family 1a1 (SLC1a1). Along with that 
finding I also identified an E2F-target gene, minichromosome maintenance 10 (MCM10), 
as being p53 regulated. Gene expression profiling of MCF7 breast cancer cells treated 
with RNAi targeting Hdm2 and HdmX in order to reactivate p53 led to increased SLC1a1 
transcript levels. DNA damage experiments in several cell lines and along with a p53 
overexpression experiment established that p53 activation unexpectedly lead to no 
transcriptional increase in SLC1a1 expression. The results suggest that SLC1a1 is not a 
transcriptional target of p53 and may have been a false positive result from the 




Gene expression profiling of MCF7 breast cancer cells treated with RNAi targeting 
Hdm2 and HdmX in order to reactivate p53 led to a transcriptional decrease in MCM10 
expression. DNA damage experiments along with siRNA targeting Hdm2 and HdmX 
established that p53 activation leads to a reduction in MCM10 transcript levels. I am able 
to show that the p53-mediated reduction of MCM10 mRNA levels is due to p53-
mediated transactivation of p21, a well-known p53 target involved in cell cycle arrest. 
These results suggest that p53 activation leads to a reduction in gene expression of E2F 
target genes involved in cell cycle progression through transactivation of p21.
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p53 also known as the “guardian of the genome” is a well-studied tumor suppressor 
protein. Its primary role is in conserving genome stability through controlling cellular 
proliferation. This is the mechanism by which it prevents genome mutation (7). The 
importance of p53 in higher level organisms can be found by its ability to regulate the 
cell cycle or induction of apoptosis (20, 29). In nearly all cases of cancer the p53 protein 
mutated and or is inactive in its function as a tumor suppressor. Inactivation of p53 can 
be due to a number occurrences like genetic mutations, or can be attributed to abnormal 
overexpression of p53’s two negative regulators, Hdm2 and HdmX. Nonetheless, 
inactivation of p53 by mutations or its two negative regulators leads to a p53 protein 
which is unable to transactivate its target genes whose gene products are involved in 
carrying out cell cycle arrest, apoptosis, DNA repair, and senescence (18, 26, 40). 
 
The list of known p53 target genes is vast and well-studied but there exist many novel 
p53 regulated genes whose identity and function still remain unknown (36). The 
importance of discovering novel p53 transcriptional targets stems from trying to establish 
a better understanding of the p53 signaling pathway. Some of the methods used to 
uncover potential p53 regulated genes are computational analysis, Chip on Chip arrays, 
and microarray technology (25, 37, 43). In this particular study we utilized a microarray 
method to search for novel p53 target genes.  
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In trying to identify novel target genes our laboratory employed a siRNA approach to 
lower levels of p53’s negative regulators, Hdm2 and HdmX. Hdm2 possesses the ability 
to inhibit p53 transcriptional activity and decrease p53 protein levels through ubiquitin 
mediated proteosomal degradation (18). HdmX shares the ability to inactivate p53 
transcriptional activity but does not possess the ability to destabilize the p53 protein via 
proteosomal degradation (14, 34). MCF7 breast cancer cells were chosen for this study 
because both Hdm2 and HdmX are found overexpressed in this cell line as compared to 
other human cell lines possessing wild-type p53 (50). Employing Affymetrix microarray 
technology, we evaluated changes in gene expression following the non-genotoxic 
activation of p53 in MCF7 cells through lowering levels of either HdmX or Hdm2. 
 
During the course of analyzing the results from the microarray experiment, Solute Carrier 
Family Member 1a1 (SLC1a1) was identified as a putative p53 transcriptional target. The 
Solute Carrier group of membrane transport proteins includes 43 families with 298 
transporter genes (9). The SLC group members transport a vast array of solutes including 
charged and uncharged organic molecules as well as inorganic ions (9). The solute carrier 
family 1 (SLC1) includes five high-affinity glutamate transporters which have a crucial 
role in protecting neurons against glutamate toxicity in the central nervous system (15). 
SLC1a1 localizes on the neuronal cell membrane and uptakes glutamate from the 
extracellular space. This function is crucial for the termination of glutamate-mediated 
signaling in synapse and also for prevention of neuronal death by suppressing glutamate 
toxicity (17). It was discovered that SLC1a1 might possess additional mechanisms in 
terms of neuronal protection. One group revealed a unique “rescue” function of SLC1a1 
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independent of removal of extracellular glutamate where SLC1a1 possesses an anti-
apoptotic function in PC12 cells which have been NGF deprived and motor neurons that 
have been injured (16). Interestingly, another lab was able to show that nerve growth 
factor withdrawal-mediated apoptosis is in some part regulated by p53 (41). All of this 
information taken together may implicate a novel p53-mediated pathway in neuronal cell 
death. 
 
Another alternative function was found by Aoyama et al  who reported that genetically 
null SLC1a1(-/-) mice have reduced levels of glutathione and with aging develop brain 
atrophy as well as behavioral changes (1). SLC1a1 has a distinguishing feature which 
allows it to bind and transport cysteine more effectively than astrocyte glutamate 
transporters (48). Cysteine is the rate-limiting substrate for the synthesis of glutathione 
which is important for the metabolism of hydrogen peroxide, nitric oxide and other 
reactive oxygen species (5). In summary this group suggested that SLC1a1 deficiency 
leads to impaired glutathione metabolism, oxidative stress and age-dependent 
neurodegeneration (1). Loss of glutathione has been used as a marker in 
neurodegenerative diseases like Alzheimer’s disease, Parkinson’s disease, and 
amyotrophic lateral sclerosis (2). It was found that glutathione depletion in neurons and 
fibroblast cells leads to increased expression and activation of p53 ultimately leading to 
cell death (6). Elucidating p53’s possible transcriptional regulation on a gene with such 
diverse functions as well as links to neurodegenerative diseases may be a huge step in 
uncovering p53’s role in brain. 
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 In most cells p53 plays vital role in the regulation of cell proliferation where in response 
to cellular stress p53 acts as a transcription factor to control a large group of genes of 
which gene products are involved in DNA repair, apoptosis, and cell cycle arrest (42). 
p53’s capacity to regulate the cell cycle comes from its ability to control expression of 
p21(or cyclin-dependent kinase inhibitor 1A) which functions by inducing G1-S arrest 
(33). p53 regulation of p21 connects p53 with the RB tumor suppressor pathway leading 
to cell cycle arrest in response to cellular stress (45). Retinoblastoma gene (RB) has the 
primary role of controlling excessive cellular growth by inhibiting cell cycle progression 
(28). Rb is a member of the pocket protein family which possesses a functional binding 
site for other proteins (19). Rb’s role to impact the cell cycle comes through its ability to 
bind the E2F transcription factor leading to a complex that inhibits E2F transactivation of 
its target genes involved in cell cycle progression (38, 39). Sequences homologous to the 
E2F DNA binding site have been found upstream of cellular genes that encode proteins 
involved in the G1-S transition and in DNA synthesis, including thymidine kinase, 
dihydrofolate reductase, DNA polymerase alpha, cdc2, c-myc, N-myc, c-myb, B-myb, and 
cyclin D1 (10, 21). 
 
Analysis of the microarray study revealed a group of E2F regulated genes involved in 
G1-S cell cycle progression that were found to be down-regulated after p53 activation via 
RNAi targeting Hdm2 and HdmX. Mcm10, an E2F targeted gene (46), was chosen as a 
putative p53 repressed gene. Mcm10 was first identified in Saccharomyces cerevisiae as 
an essential DNA replication factor whom participates in an important role in the pre-RC 
assembly (23). Mcm10 proceeds the loading of the MCM 2-7 complex onto replication 
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origins (13) and interacts genetically with Cdc45 and DNA polymerases (12). 
Knockdown of Mcm10 using RNA interference lead to G2 arrest caused by slow and 
incomplete replication (32). 
 
In this present study, I examined two genes detected as potential p53 regulated genes. 
First, SLC1a1 represented a novel p53 induced gene. Consequently, a number of DNA 
damaging experiments were performed to monitor SLC1a1 expression in response to 
cellular stress. Alternatively, RNAi targeting Hdm2 and HdmX along with p53 
overexpression were carried out to monitor SLC1a1 transcript levels. I show that SLC1a1 
expression is increased in response to activation of p53 by RNAi targeting its two 
negative regulators but its expression does not respond like a well-known p53 target in 
terms of cellular stress or p53 overexpression. 
 
Secondly, I examined a group of E2F-1 regulated genes (MCM10, E2F-1, and cyclin A2) 
that appeared uniformly repressed by p53 activation. I was able to show that p53 
regulates E2F-1 targets involved in G1-S cell cycle progression. I was also able to show 
that p53 activation leading to down-regulation of E2F-1 targets is through transactivation 
of p21. Through knocking-down expression of p21, the down-regulation of E2F-1 targets 














 The human tumor cell lines, U87 (glioblastoma), MCF7 (breast carcinoma), 
HCT116-p53+/+ and HCT116-p53-/- (colorectal carcinoma), MCF10A (mammalian 
mammary epithelial), H1299 (non-small cell lung carcinoma), HCN2 (primary cortical 
neurons) were grown in Dulbecco’s modified Eagle medium(DMEM) supplemented with 
10% bovine growth serum (BGS) and 10 μg/mL gentamicin unless otherwise indicated. 
siGENOME duplex RNA targeting mRNA from HdmX, Hdm2, p53, p21, and a non-
targeting control siRNA were obtained from Dharmacon Research, Inc. and siRNA 
transfection was using Oligofectamine or Lipofectamine 2000 (Invitrogen) as described 
below. Doxorubicin hydrochloride, bleomycin, and AraC were all purchased from Sigma, 




 MCF7 and MCF10A cells were reverse transfected at the time of seeding plus 
transfected again 24 hours later. Cells were seeded at 200,000 cells per well in 6-well 
plates, in antibiotic free DMEM containing 1% BGS in a small volume. Cells were 
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reverse transfected with 100 nM siRNA (Dharmacon Research, Inc) using Lipofectamine 
2000 (Invitrogen). 
  
 24-well plate 6-well plate 6-cm dish 
Cell Number 100,000/well 200,000/well 700,000/dish 
Volume of  
siRNA + SFM 
2.5 μL siRNA + 
182.5 μL SFM 
5 μL siRNA + 180 
μL SFM 
7.5 μL siRNA + 




1.5 μL lipid +  
113.5 μL SFM 
3 μL lipid +  
112 μL SFM 
4.5 μL lipid +  
110.5 μL SFM 
Total Volume 0.5 mL 1.0 mL 1.5 mL 
Table 1. Volumes of siRNA, lipid, and serum free media (SFM) for siRNA 
transfections. The table lists the appropriate volumes of each component necessary to 
setup a 100 nM siRNA transfection in the various cell culture vessels. 
 
Upon a five hour incubation, media was removed and cells were re-feed with DMEM 
containing 10% BGS. Twenty hours later, cells were transfected again with 100 nM 
siRNA in a small volume of serum free media using Oligofectamine (Invitrogen). After a 
four hour incubation, an equal volume of 20% serum DMEM is added to each well/dish 
without removing the transfection mixture. Total RNA was isolated 24 hrs post the last 
siRNA transfection unless indicated otherwise. 
 
Plasmids and Transfections 
 
 For ectopic expression of p53: pcDNA3.1-p53, pcDNA3.1-mutant p53(R175H), 
pcDNA3.1-EGFP. Transient transfections of these plasmids were carried out using 
 7
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lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions, with 




 Cells were harvested directly in the culture dish and total RNA was isolated using 
the RNeasy kit (Qiagen) according to manufacturer’s protocol. The RNA was quantified 
by spectrophotometer reading at 260 nm. Next, 1 μg RNA was reverse transcribed with 
random hexamers to create cDNA using the TaqMan Reverse Transcription kit (Applied 
Biosystems). Quantitative PCR was performed in a 96-well plate on an ABI Prism 
7900HT sequence detection system using 1 μl cDNA per well, TaqMan Universal PCR 
master mix and Assay-On-Demand Gene Expression products (Applied Biosystems) 
specific for genes of interest. Each cDNA sample was analyzed in triplicate and fold 
change relative to control was calculated based on a PCR efficiency of two and 
normalized to GAPDH (endogenous control) RNA levels using SDS 2.0 Software (ABI). 
Average fold change and standard deviation were obtained from 2-3 biological replicate 







III. Results: Part 1 
 
List of 13 known p53 targets up-regulated upon activation of p53.  Microarray results 
provided a list of known p53 target genes that were all seen to be up-regulated by 
activation of p53 via usage of siRNA targeting Hdm2 or HdmX (Figure 1). As expected 
these genes were increased upon siHdm2 or siHdmX but had comparable or lower 
transcript levels than siCon when treated with siHdmX+sip53 or sip53.  Results for 
SLC1a1 followed a similar pattern as compared to these known p53 target genes (Figure 
2). So, it seemed feasible to consider SLC1a1 as a possible candidate for a novel p53 
transcriptional target. 
 
SLC1a1 transcript levels are increased upon activation of p53. Based on microarray 
results I hypothesized that SLC1a1 might be a possible transcriptional target of p53. To 
test this hypothesis, the first experiment performed was to validate the microarray results 
showing up-regulation of SLC1a1 following RNAi induced p53 activation. MCF7 cells 
were reverse transfected (See Materials and Methods) with various RNAi combinations 
and upon completion of the protocol cells were harvested for RNA extraction ultimately 
leading to RT-qPCR. qPCR results showed that SLC1a1 transcript levels were increased 
greater than two-fold upon simultaneously knocking down Hdm2 and HdmX (Figure 3). 
Intriguingly, knock-down of either Hdm2 or HdmX did not result in a statistical 
significant increase in SLC1a1 mRNA levels. This may be due to the effectiveness of  
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Figure 1: GeneChip expression of 13 known p53-regulated genes that were induced 
by knockdown of either siHdmX or siHdm2.  Y-axis represents the average fold 
change (log2) for each of the genes in the indicated RNAi transfections relative to siCon 






































Figure 2: GeneChip relative expression of SLC1a1 in MCF7 cells treated with the 
indicated RNAi. Y-axis represents the average fold change for SLC1a1 in the indicated 






















































Figure 3: Induction of SLC1a1 by hdm2/hdmX knockdown using RNAi. MCF7 cells 
were reverse transfected (see Materials and Methods). Twenty-four hours after 
transfection of RNAi combinations, RNA was isolated and subjected to RT-qPCR to 
quantify expression of SLC1a1 using GAPDH expression for normalization. Expression 
levels (Y-axis) were relative to Mock and reported as fold changes. Error bars represent 







knocking-down expression of Hdm2 and HdmX. In terms of the microarray experiment, 
RNAi transfections resulted in a greater than 80% reduction of Hdm2 and HdmX 
expression (data not shown) where as I was only able to achieve a reduction of 64% for 
Hdm2 and 48% for HdmX (Figure 4). Also interestingly, SLC1a1 transcript levels were 
reduced by 60% upon knocking down expression of p53. Expression levels of p21, a 
well-known p53 target, were also examined. p21 transcript levels were increased (Figure 
5) upon knocking down expression of Hdm2 (~4-fold) or HdmX (~4-fold) along with the 
combination of Hdm2 and HdmX (greater than 8-fold). p21 levels also decreased by 40% 
upon knocking-down p53. Similarly to p21, SLC1a1 transcript levels are increased upon 
activation of p53 by concurrently knocking down p53’s negative regulators Hdm2 and 
HdmX. 
 
SLC1a1 transcript levels are decreased upon activation of p53 via doxorubicin 
treatment in U87 cells. Doxorubicin is a DNA damaging agent that has the ability to 
intercalate into the DNA and cause double-strand DNA breaks eliciting a p53 response 
(22). Testing the effect of doxorubicin on SLC1a1 expression, U87 glioblastoma cells 
were treated with increasing amounts of doxorubicin over a twenty-four hour period. At 
the end of twenty-four hours cells are harvested and RNA was extracted in order to 
perform RT-qPCR. While, p21 transcript levels were increased (Figure 6) around 7-fold 
upon addition of 0.25 μg/mL doxorubicin, SLC1a1 transcript levels were decreased 
upwards of 50% after the same doxorubicin treatment (Figure 7). It was observed that 
administering more than 0.5 μg/mL doxorubicin was toxic to these U87 cells. The 

























































Figure 4: hdm2, p53, and hdmX knockdown using RNAi. MCF7 cells were reverse 
transfected (see Materials and Methods). Twenty-four hours after transfection RNA was 
isolated and subjected to RT-qPCR to quantify expression of hdm2, hdmX, and p53 after 
normalization to GAPDH. Expression levels (Y-axis) were relative to Mock and reported 
































































Figure 5: Induction of p21 by hdm2 or hdmX knockdown using RNAi. MCF7 cells 
were reverse transfected (see Materials and Methods). Twenty-four hours after 
transfection RNA was isolated and subjected to RT-qPCR to quantify expression of p21 
after normalization to GAPDH. Expression levels (Y-axis) were relative to Mock and 


















































Figure 6: p21 transcript levels are increased upon doxorubicin treatment. U87 cells 
were treated with increasing amounts of doxorubicin. Twenty-four hours after application 
of the damaging agent, RNA was isolated and subjected to RT-qPCR to quantify 
expression of p21 after normalization to GAPDH. Expression levels (Y-axis) were 
relative to untreated and reported as fold changes. Error bars represent the 95% 




















































Figure 7: SLC1a1 transcript levels are decreased upon doxorubicin treatment. U87 
cells were treated with increasing amounts of doxorubicin. Twenty-four hours after 
application of the damaging agent, RNA was isolated and subjected to RT-qPCR to 
quantify expression of SLC1a1 after normalization to GAPDH. Expression levels (Y-
axis) were relative to untreated and reported as fold changes. Error bars represent the 
95% confidence interval of the relative expression.
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death. As expected, p21 transcript levels were increased upon activation of p53 via DNA 
damage. Conversely, doxorubicin treatment in U87 cells did not lead to an induction of 
SLC1a1 as proposed, in fact SLC1a1 transcript levels were decreased upon doxorubicin 
treatment in U87 cells. 
 
SLC1a1 transcript levels are not altered after addition of doxorubicin in MCF7 
cells. Using the same damaging agent but different cell line, I sought out to determine 
whether cell line specificity had an effect on SLC1a1 gene expression. MCF7 breast 
cancer cells were treated with increasing doses of doxorubicin over a twenty-four period. 
After drug treatment, cells were harvested for RNA in order to perform qPCR to monitor 
the transcript levels of SLC1a1. Here, I used a lower range of doxorubicin in an attempt 
to avoid cellular toxicity. Unlike my previous result showing a decrease in SLC1a1 
transcript levels upon doxorubicin treatment in U87 cells, SLC1a1 transcript levels in 
MCF7 cells treated with doxorubicin showed no change at the two lowest doses of 
damage where at 0.3 μg/mL SLC1a1 mRNA levels did not increase 2-fold or more 
(Figure 8). p21 transcript levels were increased 4-fold after addition of 0.3 μg/mL 
doxorubicin (Figure 8). Taken together, MCF7 cells treated with increasing doses of 
doxorubicin lead to a p53 response that unaltered increased SLC1a1 gene expression. 
 
SLC1a1 is non-responsive to DNA damage in mammary epithelial cells. Using a 
mammalian mammary epithelial cell line wild-type for p53 that is immortialized but not 
transformed, I sought out to test whether DNA damage in a non-cancerous cell line 












































Figure 8: SLC1a1 transcript levels are unaffected upon doxorubicin treatment. 
MCF7 cells were treated with increasing amounts of doxorubicin. Twenty-four hours 
after application of the damaging agent, RNA was isolated and subjected to RT-qPCR to 
quantify expression of SLC1a1 and p21 after normalization to GAPDH. Expression 
levels (Y-axis) were relative to untreated and reported as fold changes. Error bars 










with increasing amounts of cytosine arabinoside also known as AraC. AraC is a DNA 
damaging agent that inhibits DNA and RNA polymerases. Twenty-fours after AraC 
treatment, cells were harvested for RNA. qPCR results illustrates that increasing amounts 
of AraC led to the expected dose-dependent increase of p21 transcripts (Figure 9). Where 
as, SLC1a1 transcripts were unaffected by the increasing amounts of AraC (Figure 10). 
In a similar experiment MCF10A cells were treated with increasing amounts of 
bleomycin, which is a DNA damaging agent that acts as a radiomimetic to cause DNA 
strand breaks. Transcript levels were monitored by qPCR and illustrate a similar trend as 
before, where p21 transcripts are increased in a dose-dependent manner (Figure 11) and 
SLC1a1 transcripts are unaltered (Figure 12). These results along with previous results 
clearly suggest that SLC1a1 gene expression is unaffected by DNA damage in this 
mammary epithelial cell line. 
 
SLC1a1 transcripts are reduced upon doxorubicin treatment in human cortical 
neurons. Though SLC1a1 is expressed in multiple tissues throughout the body (kidney, 
liver, etc.) its relation to disease is found predominantly in the brain, neurons in 
particular. When compared to the previously described cell line (MCF7, MCF10A, U87) 
HCN2 cells which are wild-type for p53 express over 100-fold higher level of SLC1a1 
mRNA (data not shown).  Doxorubicin administration to HCN2 cells was used to assess 
the effect of DNA damage on SLC1a1 gene expression in this particular cell line. qPCR 
results showed damage response that lead to a 4-fold induction of p21 transcripts at 0.25 














































Figure 9: p21 transcript levels are increased upon AraC treatment. MCF10A cells 
were treated with increasing amounts of AraC. Twenty-four hours after application of the 
damaging agent, RNA was isolated and subjected to RT-qPCR to quantify expression of 
p21 after normalization to GAPDH. Expression levels (Y-axis) were relative to untreated 



















































Figure 10: SLC1a1 transcript levels are unaffected upon AraC treatment. MCF10A 
cells were treated with increasing amounts of AraC. Twenty-four hours after application 
of the damaging agent, RNA was isolated and subjected to RT-qPCR to quantify 
expression of SLC1a1 after normalization to GAPDH. Expression levels (Y-axis) were 
relative to untreated and reported as fold changes. Error bars represent the 95% 














































Figure 11: p21 transcript levels are increased upon AraC treatment. MCF10A cells 
were treated with increasing amounts of AraC. Twenty-four hours after application of the 
damaging agent, RNA was isolated and subjected to RT-qPCR to quantify expression of 
p21 after normalization to GAPDH. Expression levels (Y-axis) were relative to untreated 

























































Figure 12: SLC1a1 transcript levels are unaffected upon bleomycin treatment. 
MCF10A cells were treated with increasing amounts of bleomycin. Twenty-four hours 
after application of the damaging agent, RNA was isolated and subjected to RT-qPCR to 
quantify expression of SLC1a1 after normalization to GAPDH. Expression levels (Y-
axis) were relative to untreated and reported as fold changes. Error bars represent the 




















































Figure 13: p21 transcript levels are increased upon doxorubicin treatment. HCN2 
cells were treated with increasing amounts of doxorubicin. Twenty-four hours after 
treatment of the damaging agent, RNA was isolated and subjected to RT-qPCR to 
quantify expression of p21 after normalization to GAPDH. Expression levels (Y-axis) 
were relative to untreated and reported as fold changes. Error bars represent the 95% 









0.25 μg/mL (Figure 14). As in previous experiments, DNA damage of HCN2 cells led to 
an expected p21 induction but unexpectedly led to a reduction in SLC1a1 transcripts. 
 
Genotoxic stress is known to initiate a p53 response which leads to transactivation of its 
target genes (30). My results from these DNA damaging experiments suggest that if 
indeed SLC1a1 is a direct transcriptional target of p53, then genotoxic stress is not the 
mechanism for its transactivation. 
 
Overexpression of p53 does not lead to an increase in SLC1a1 transcript levels. After 
testing a number of DNA damaging agents in several cell lines, I next wanted to assess 
the effect of overexpression of p53 on SLC1a1 gene expression. Using H1299 cells (non-
small cell lung carcinoma which are null for p53), expression plasmids containing either 
a empty vector, wild-type p53, mutant p53, and the combination of both were transfected 
(See Materials and Methods) into these cells. Upon conclusion of the protocol, RNA is 
isolated and subjected to RT-qPCR. As shown, p21 transcripts are increased 25-fold 
(Figure 15) upon overexpression of p53. Mutant p53 results proved to be inconclusive 
due to high levels of variability (Figure 15) while the combination of both wild-type and 
mutant p53 lead to a decrease in p21 transcript levels when compared to H1299 cells 
overexpressing wild-type p53 (Figure 15). SLC1a1 transcript levels were shown be 
unaffected by overexpression of either wild-type or mutant p53 (Figure 16). In summary, 
overexpression of p53 led to a robust induction of its known target p21 while 















































Figure 14: SLC1a1 transcript levels are decreased upon doxorubicin treatment in 
HCN2 cells. HCN2 cells were treated with increasing amounts of doxorubicin. Twenty-
four hours after treatment with the damaging agent, RNA was isolated and subjected to 
RT-qPCR to quantify expression of SLC1a1 after normalization to GAPDH. Expression 
levels (Y-axis) were relative to untreated and reported as fold changes. Error bars 



































Figure 15: Overexpression of p53 leads to an increase in p21 transcript levels. H1299 
were transfected (See Materials and Methods) with the indicated expression plasmids. 
Upon completion of transfection cells were harvested for RNA which was subjected to 
RT-qPCR to quantify expression of p21 after normalization to GAPDH. Expression 
levels (Y-axis) were relative to CMV and reported as fold changes. Error bars represent 

































































Figure 16: Overexpression of p53 has little to no effect on SLC1a1 transcript levels. 
H1299 were transfected (See Materials and Methods) with the indicated expression 
plasmids. Upon completion of transfection cells were harvested for RNA which was 
subjected to RT-qPCR to quantify expression of SLC1a1 after normalization to GAPDH. 
Expression levels (Y-axis) were relative to CMV and reported as fold changes. Error bars 
represent the 95% confidence interval of the relative expression. 
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IV. Results: Part 2 
 
List of genes that are down-regulated upon activation of p53 by RNAi targeting 
HdmX and Hdm2. While p53 activation through Hdm2 and HdmX knockdown was 
expected to result transcriptional up-regulation of target genes, we also uncovered a 
group of genes demonstrating what appeared to be a p53-dependent downregulation 
(Figure 17). Comprised within this list of genes was a subset of genes with gene products 
that are involved in the G1-S transition of the cell cycle. Most interestingly was that, the 
all of these genes, downregulated following HdmX and Hdm2 knockdown had the 
commonality of being E2F1 target genes. 
 
MCM10 transcript levels are decreased upon activation of p53 by RNAi targeting 
Hdm2 and HdmX. To further examine this subset list of genes that were down-regulated 
after p53 was activated, an E2F1 target gene-MCM10 (46) was used to assess p53’s 
ability to repress this group of E2F1 targets. The MCM family consist of a number of 
genes (2-7 including 10) all in which are involved in DNA replication, specifically, the 
MCM2-7 complex encode proteins that are seen to act as the DNA helicase in initiation 
of DNA replication (3). MCM10 has been found to be an essential component of the 
replication fork along with being required to maintain DNA polymerase alpha on the 
chromatin (35). The MCM genes encode proteins that are involved in G1-S phase 
transition (44) and are known E2F target genes (24, 31, 46). 
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Figure 17. GeneChip expression of 13 reported E2F1-regulated genes that were 
repressed by knockdown of either siHdmX or siHdm2.  Y-axis represents the average 
fold change (log2) for each of the genes in the indicated RNAi transfections relative to 




To test if loss of Hdm2 or HdmX results in repression of E2F-1 regulated genes involved 
in cell cycle progression, I monitored MCM10 and how its transcript levels are 
modulated in relation to p53 activation. Having identified MCM10 as potentially 
repressed by activation of p53, I next set out to validate this microarray finding (Table 2) 
by repeating the siRNA transfections in MCF7 breast cancer cells and employing RT-
qPCR to examine the expression of MCM10 relative to GAPDH. siRNA targeting the 
indicated gene was reverse transfected into MCF7 cells as described in the  Materials and 
Methods section. Subsequent RT-qPCR from RNAi transfected MCF7 cells suggests that 
indeed MCM10 transcipt levels decrease upon activation of p53: 25% reduction by 
siHdm2, 60% reduction by siHdmX, 66% reduction by siHdm2/HdmX (Figure 18). Also, 
MCM10 transcript levels were increased upon sip53 and had levels comparable to siCon 
in terms of siHdmX/sip53. I propose that the repression of MCM10 may be p53-
dependent shown by the fact that simultaneous removal of p53 and HdmX blocks the 
decrease one achieves by removing HdmX alone. Activation of p53 by knocking-down 
expression of its two negative regulators leads to a decrease in MCM10 transcript levels. 
 
MCM10 transcript levels are reduced following of DNA damage in MCF7 breast 
cancer cells.  Cellular stress or DNA damage has been shown to elicit a p53 response in 
cells harboring a functional p53. In order to test if MCM10 gene expression was inhibited 
following DNA damage, I exposed MCF7 cells to increasing amounts of doxorubicin. 
qPCR results illustrate that increasing amount of doxorubicin leads to a reduction in 
MCM10 mRNA levels (Figure 19). In another experiment, I treated MCF7 cells with 

























Affymetrix GeneChip Results for 
MCM10
Relative Expression
(1.041 to 1.25)1.159 Treatment type Treatment type sip53 
(1.306 to 1.406)1.349 Treatment type siX(A)/sip53
(0.599 to 0.616)0.61 Treatment type siHdmX(B)
(0.469 to 0.614)0.546 Treatment type siHdmX(A)
(1.007 to 1.094)1.063 Treatment type siHdm2(B)
(0.411 to 0.451)0.431 Treatment type siHdm2(A)
(.873 to 1.094)1.004 Treatment type siCon
(.808 to 1.095)0.958 Treatment type Mock
Relative Expression Range
Table 2: GeneChip relative expression of MCM10 under indicated RNAi 











































Figure 18: Repression of MCM10 by hdm2 or hdmX knockdown using RNAi. 
MCF7 cells were reverse transfected (see Materials and Methods). Twenty-four hours 
after transfection RNA was isolated and subjected to RT-qPCR to quantify expression of 
MCM10 after normalization to GAPDH. Expression levels (Y-axis) were relative to 
siControl and reported as fold changes. Error bars represent the 95% confidence interval 






































Figure 19: MCM10 transcript levels are reduced following doxorubicin treatment. 
MCF7 cells were treated with increasing amounts of doxorubicin. Twenty-four hours 
after application of the damaging agent, RNA was isolated and subjected to RT-qPCR to 
quantify expression of MCM10 after normalization to GAPDH. Expression levels (Y-
axis) were relative to untreated and reported as fold changes. Error bars represent the 









levels. Here, qPCR results again showed that increasing amounts of UV-C irradiation 
lead to decrease in MCM10 transcript levels (Figure 20). As seen in both cases, 
increasing amounts of either doxorubicin or UV-C irradiation caused a reduction in 
MCM10 transcript levels. Both cases clearly indicate that DNA damage in MCF7 cells 
leads to a decrease in MCM10 mRNA levels. 
 
MCM10 transcript levels are reduced upon UV-C irradiation in MCF10A 
mammalian mammary epithelial cells.  The next experiment performed was one 
intended to answer the question of whether DNA damage induced repression of MCM10 
is limited to MCF7 breast cancer cells and to test if the repression can be observed in a 
non-transformed epithelial cell line. To address these questions MCF10A cells (which are 
immortalized, non-transformed mammalian mammary epithelial cells) were treated with 
increasing amounts of UV-C irradiation. From the RT-qPCR results it was concluded that 
indeed MCM10 transcript levels are reduced at high levels of UV-C (47% reduction at 
250 J/m2 and 80 % reduction at 500 J/m2 UV-C irradiation) in MCF10A breast epithelial 
cells (Figure 21). In two cell lines derived from the breast tissue, one being cancerous 
(MCF7) and other being mammary epithelial (MCF10A) MCM10 transcripts levels are 
decreased upon increasing amounts of UV-C irradiation. 
 
MCM10 transcript levels are not reduced in HCT116 -/-p53 upon UV-C irradiation. 
Activation of p53 by either DNA damage or by RNAi targeting its two negative 
regulators Hdm2 or HdmX leads to a reduction in the transcript levels of MCM10. The 








































Figure 20: MCM10 transcript levels are reduced upon UV-C irradiation. MCF7 cells 
were treated with increasing amounts of UV-C irradiation. Twenty-four hours after 
application of the damaging agent, RNA was isolated and subjected to RT-qPCR to 
quantify expression of MCM10 after normalization to GAPDH. Expression levels (Y-
axis) were relative to untreated and reported as fold changes. Error bars represent the 










































Figure 21: MCM10 transcript levels are decreased upon UV-C irradiation in 
mammary epithelial cells. MCF10A cells were subjected to increasing amounts of UV-
C irradiation. Twenty-four hours after irradiation, cells were harvested and RNA was 
isolated. RT-qPCR was then performed to quantify expression of MCM10 after 
normalization to GAPDH. Expression levels (Y-axis) were relative to untreated and 





damaging experiment assessing MCM10 transcript levels. The cell line chosen was 
HCT116 -/-p53 human colorectal cancer cells. These cells were treated with increasing 
amounts of UV-C irradiation. Results exemplify that MCM10 transcript levels are not 
reduced in HCT116 -/-p53 cells treated with increasing amounts of UV-C irradiation 
(Figure 22). In a separate experiment, HCT116 cells that possess wild-type p53 were 
treated with increasing amounts of UV-C irradiation. In contrast with the previous result, 
MCM10 transcript levels were reduced 60% at the lowest dose of irradiation (Figure 23). 
Thus, the reduction of MCM10 transcript levels by DNA damage may be p53-dependent. 
 p53 activation by siRNA targeting Hdm2/HdmX or by DNA damage leads to an 
induction of its well known target gene p21. p21, also known as cyclin-dependent kinase 
inhibitor 1A, can inhibit CDK/cyclins involved in the phosphorylation of Rb which 
relieves E2F-1 from the Rb-E2F1 complex allowing E2F-1 transactivation of its target 
genes (4). Thus, p53 activation through DNA damage or RNAi targeting HdmX or Hdm2 
would lead to increased p21 levels which in turn may lead to repression of E2F-1 target 
genes through inhibiting Rb phosphorylation. 
 
siRNA targeting p21 has little to no effect on MCM10 transcript levels. Employing 
multiple siRNA constructs targeting p21, I set out first to test whether knocking-down 
endogenous expression of p21 has any effect on steady-state MCM10 transcript levels. 
sip21 constructs 1 and 3 led to over 95% reduction of p21 transcript levels (Figure 24). 
Interestingly, these siRNA constructs did not lead to a pronounce change in MCM10 
transcript levels (Figure 25). A possible explanation is that endogenous p21 does not 












































Figure 22: MCM10 transcript levels are not decreased upon UV-C irradiation in 
HCT116 -/-p53 colorectal cancer cells. HCT116 -/- cells were subjected to increasing 
amounts of UV-C irradiation. Twenty-four hours after irradiation, cells were harvested 
and RNA was isolated. RT-qPCR was then performed to quantify expression of MCM10 
and p21 after normalization to GAPDH. Expression levels (Y-axis) were relative to 
untreated and reported as fold changes. Error bars represent the 95% confidence interval 




















































Figure 23: MCM10 transcript levels are decreased upon UV-C irradiation in 
HCT116 +/+ p53 colorectal cancer cells. HCT116 +/+ cells were subjected to 
increasing amounts of UV-C irradiation. Twenty-four hours after irradiation, cells were 
harvested and RNA was isolated. RT-qPCR was then performed to quantify expression of 
MCM10 after normalization to GAPDH. Expression levels (Y-axis) were relative to 
untreated and reported as fold changes. Error bars represent the 95% confidence interval 




















































Figure 24: sip21 decreases p21 transcript levels. MCF7 breast cancer cells were 
reverse transfected(See Materials and Methods) with the indicated RNAi targeting p21. 
Twenty-four hours later, RNA was isolated and subjected to RT-qPCR to quantify 
expression of p21 after normalization to GAPDH. Expression levels (Y-axis) were 
relative to Mock transfection(MCF7 cells) and reported as fold changes. Error bars 
























































Figure 25: siRNA targeting p21 has little to no effect on MCM10 transcript levels. 
MCF7 breast cancer cells were reverse transfected(See Materials and Methods) with the 
indicated RNAi targeting p21. Twenty-four hours later, RNA was isolated and subjected 
to RT-qPCR to quantify expression of MCM10 after normalization to GAPDH. 
Expression levels (Y-axis) were relative to Mock transfection(MCF7 cells) and reported 






DNA damage or RNAi targeting HdmX/Hdm2) is essential in the down-regulation of 
MCM10 transcript levels stemming from increased levels of p21.  
 
Repression of MCM10 by RNAi targeting Hdm2 is blocked by concurrent p21 
knockdown. If in fact the increased levels of p21 (by p53 activation) is the critical 
effector in the down-regulation of E2F-1 targets, activation of p53 along with 
simultaneously knocking-down p21 expression should abrogate the repression seen by 
solely knocking down Hdm2 or HdmX. Therefore, MCF7 cells were reverse transfected 
as described in the Materials and Methods section with siHdm2 alone or in combination 
with sip21. As expected, MCM10 levels are reduced 50 % by knocking down Hdm2 with 
a concomitant increase in p21 levels (Figure 26). Conversely, the simultaneous knock-
down of p21 and Hdm2 completely abrogated the repression of MCM10 gene expression. 
Similar results were seen when using siHdmX alone or in combination with sip21 (data 
not shown). These results suggest that p53 activation inactivates E2F-1 transactivation 
via p21 induction. 
 
Repression of E2F-1 targets by RNAi targeting Hdm2 or HdmX is blocked by 
concurrent p21 knockdown. MCM10 was a member of a large list of E2F-1 targets that 
were repressed upon activation of p53. Next, I wanted to choose other known E2F-1 
targets to determine if they were also possibly regulated by p53 through p21 induction. In 
MCF7 breast cancer cells, using E2F-1 (which targets itself), along with cyclin A2, and 
MCM4 (a family member of MCM10) I monitored their transcript levels in response to 






















siCon 1 1 1
siHdm2 0.51571 4.908507 0.155
siHdm2 + sip21 0.95777166 0.45220748 0.173
































Figure 26: Repression of MCM10 by hdm2 knockdown is blocked by concurrent 
knockdown of p21. MCF7 breast cancer cells were reverse transfected (See Materials 
and Methods) with the indicated RNAi combinations. Twenty-four hours later, RNA was 
isolated and subjected to RT-qPCR to quantify expression of MCM10 after normalization 
to GAPDH. Expression levels (Y-axis) were relative to siCon and reported as fold 
change. Error bars represent the 95% confidence interval of the relative expression. 
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were reduced by 47% while E2F-1 levels dropped off by 57% (Figure 27) MCM4 
transcripts were reduced by 25% (Figure 28). RNAi targeting HdmX led to a reduction of 
cyclin A2 levels by 89% while decreasing E2F-1 levels by 58% (Figure 27), where 
MCM4 levels were also reduced by 45% (Figure 28). Just as before, concurrent knock-
down of the Hdms and p21 completely abrogated MCM4, E2F-1, and cyclin A2 
repression. 
  
Repression of E2F-1 targets by siHdm2 is blocked by concurrent p21 knockdown in 
mammalian mammary epithelial cells. In the previous experiments I was able to 
illustrate that three E2F-1 target genes (MCM10, cyclin A2, E2F-1) are all repressed by 
p53 activation through p21 induction. These experiments were done in MCF7 breast 
cancer cells where both Hdm2 and HdmX are overexpressed. To test if the repression can 
be observed in a non-transformed epithelial cell line, I choose MCF10A cells to assess if 
activating p53 by targeting its negative regulator could lead to a repression of the same 
E2F-1 targets. Using RNAi targeting Hdm2 I was able to show repression of all three 
genes: MCM10 37%, E2F-1 46%, Cyclin A2 42% (Figure 29). The same as in MCF7 












































Figure 27: Repression of E2F-1 targets by hdm2 and hdmX knockdown is blocked 
by concurrent knockdown of p21. MCF7 breast cancer cells were reverse 
transfected(See Materials and Methods) with the indicated RNAi combinations. Twenty-
four hours later, RNA was isolated and subjected to RT-qPCR to quantify expression of 
Cyclin A2 and E2F-1 after normalization to GAPDH. Expression levels (Y-axis) were 
relative to siCon and reported as fold changes. Error bars represent the 95% confidence 



















































Figure 28: Reduction of MCM4 transcripts by hdm2 and hdmX knockdown is 
blocked by concurrent knockdown of p21. MCF7 breast cancer cells were reverse 
transfected(See Materials and Methods) with the indicated RNAi combinations. Twenty-
four hours later, RNA was isolated and subjected to RT-qPCR to quantify expression of 
MCM4 after normalization to GAPDH. Expression levels (Y-axis) were relative to siCon 


















































Figure 29: Repression of E2F-1 targets by sihdm2 is blocked by concurrent 
knockdown of p21 in mammalian mammary epithelial cells. MCF10A mammary 
epithelial cells were reverse transfected(See Materials and Methods) with the indicated 
RNAi combinations. Twenty-four hours later, RNA was isolated and subjected to RT-
qPCR to quantify expression of MCM10, Cyclin A2 and E2F-1 after normalization to 
GAPDH. Expression levels (Y-axis) were relative to siCon and reported as fold changes. 










Human tumors employ a number of different genetic mechanisms to inactivate p53 
function. More important to this study are tumor cell lines where one or both of p53’s 
negative regulators, Hdm2 and HdmX, are overexpressed leading to loss of p53 
functionality. Using a RNAi approach along with DNA microarrays, we set out to better 
understand the effect of activation of p53 in cells in which Hdm2 and or HdmX are 
overexpressed. The DNA microarray experiment was used to first test the effect of 
knocking-down both Hdm2 and HdmX on known p53 regulated genes, but also provided 
a means of discovering possible novel p53 regulated genes. 
 
SLC1a1 was a gene that was seen to be increased upon knocking down either Hdm2 and 
HdmX; these results come directly from the microarray experiment (Figure 2) along with 
a subsequent experiment in MCF7 where both Hdm2 and HdmX expression were 
knocked-down (Figure 3). Following these two experiments, a number of DNA damaging 
experiments were performed to activate wild-type p53 in response to cellular stress. 
Results from these experiments suggested that SLC1a1 gene expression was either 
unaltered (Figures 10, 12) or decreased (Figures 5, 14) by genotoxic stress. p21, a well-
known p53 target gene, was used as a positive control in which its transcript levels were 
increased (Figures 5, 10, 12, 14). This suggests that SLC1a1 is not transactivated by 
cellular stress which is counterintuitive in terms of being a possible p53 target gene. 
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Another experiment in which p53 was overexpressed provided results that suggest that 
SLC1a1 gene expression is unaltered by p53 overexpression, while p21 transcript levels 
were increased as much as 25-fold (Figure 15). Taking all of these results into account, 
SLC1a1 does not appear to fit the classic model for acting as a p53 transcriptional target 
gene. My reasoning for last statement is because SLC1a1 expression was not induced due 
to cellular stress or overexpression of p53.  To understanding p53’s possible regulation 
on SLC1a1 gene expression, implementing other mechanisms in which p53 is activated 
in a non-genotoxic fashion may prove to be a better approach.   
 
Though not a probable direct transcriptional target, SLC1a1 may still be regulated by p53 
through an indirect mechanism being cell cycle arrest. Re-activating p53 in MCF7 cells 
by knocking-down either Hdm2 or HdmX resulted in a growth arrest with no detectable 
apoptosis (data not shown). So it may be possible that SLC1a1 gene expression is 
regulated by the cell cycle which in turn is influenced by p53 activity. To test this 
hypothesis, a cell cycle arrest assay (serum deprivation, aphidicolin treatment, etc) may 
prove to be helpful in uncovering if the cell cycle indeed has any effect on SLC1a1 gene 
expression. Another possible explanation for the increased expression of SLC1a1 upon 
re-activating p53, is that Hdm2 and HdmX could be working independently of p53 and 
possess a regulatory function on SLC1a1. Though Hdm2 and HdmX are critical to 
regulating p53, both Hdm2 and HdmX have been found to possess functions independent 
of p53. In the absence of p53, Mdm2 still plays a role in cell cycle control, DNA repair, 
and transcriptional regulation (49). MdmX has been found to have a surprising role in 
suppressing tumorigenesis by promoting centrosome clustering and bipolar mitosis (27). 
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So, it is also possible that SLC1a1’s gene expression may be regulated by Hdm2 or 
HdmX irrespective of p53 through a cellular process listed above (cell cycle control, 
DNA repair, bipolar mitosis). There are many possibilities to test this hypothesis 
experimentally, one might to use RNAi targeting Hdm2 or HdmX in a cell line which 
does not possess p53 and then study SLC1a1 gene expression.  
 
Another interesting finding within the microarray data was a subgroup of genes that were 
repressed upon Hdm2 and Hdm2 knockdown that could be classified as known E2F-1 
regulated genes. Using one of these known E2F-1 targets, MCM10, I set out to uncover 
p53’s regulation on E2F-1 targets and the global impact of this effect. Through 
performing a number of experiments in which p53 was activated, by RNAi targeting 
Hdm2 and HdmX or DNA damaging experiments, it was shown that activation of p53 
leads to de-regulation of the E2F-1 pathway involved in cell cycle progression. I was also 
able to discover that p53-mediated activation of p21 was responsible for this down-
regulation. Other groups have noted that p53 activation of p21 could lead to repression of 
Chk2 (8) but little is known about the global impact of this effect. p21 has the ability to 
inhibit CDKs (11) causing cell cycle arrest by limiting the ability of E2F-1 to 
transactivate its G1-S cell cycle progression target genes. I would like to uncover the 
biological significance of this observation. That is, what is the importance of E2F-1 
deregulation on the arrest of the cell cycle mediated by p53? Another interesting aim 
would be to fully understand whether the induction of p21 has any effect on p53-
mediated apoptosis. These findings would enable us to fully understand the importance of 
induction of p21 on p53-mediated processes (cell cycle arrest vs apoptosis). 
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Re-activation of p53 by RNAi targeting its two negative regulators provided insight both 
on known p53 targets but also opened the possibility for finding possible novel p53 
regulated genes. Through microarray findings, SLC1a1 was deemed a possible 
transcriptional target of p53. Experimental data showed that SLC1a1 gene expression was 
not induced under cellular stress or by p53 overexpression. These results suggest that 
SLC1a1 does not appear to be a direct target of p53. p53 regulation may be direct through 
p53’s ability to act as a transcription factor but p53 regulation can also be indirect. Upon 
activation of p53 by loss of Hdm2 and HdmX indirect regulation leads to a p53-
dependent decrease of E2F-1 targets through induction of p21. Taking all these findings 
into considerations, elucidating possible novel p53 regulated genes may lead to 
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